Kenvue Inc.

KVUE

Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$22.00 172,800,000 Positive High 44.56%

Offering Team

Deal Managers

  • Goldman Sachs
  • J P Morgan Chase
  • Bank of America Merrill Lynch

Lawyers

  • Cravath, Swaine & Moore LLP

Auditors

  • PricewaterhouseCoopers LLP

Pre-IPO Investors

Investors

  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

We are the world’s largest pure-play consumer health company by revenue with $15.1 billion in net sales in 2021. We combine the power of science with meaningful human insights and digital-first capabilities, which we believe empowers approximately 1.2 billion people to live healthier lives every day. Our differentiated portfolio of iconic brands—including Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec and Nicorette—is built for moments that unique More

Deal Tracker

Investors

Filing

03 May, 2023

Offer

04 May, 2023

Look Ahead

Lock Up Expiry

04 Nov, 2023

Earning

Nov 1, 2018

IPO Terms

Offer Price $22.00
Offer Size 172M

Market Sentiments

Stock Price